Weinberg Eric's Form 4 filing
RxSight, Inc. (RXST) · filed Sep 9, 2026
- Accession no.
- 0001193125-26-386840
- Filed
- Sep 9, 2026, 8:55 PM ET
- Trade date
- Sep 5, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 10 derivative transactions. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weinberg EricCIK 0001295814 | Officer (See remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 5, 2026 | Common Stock | DReturned to the companyDisposed | −87,437 | –F1 | – | 0 | Direct | |
| Sep 5, 2026 | Common Stock | DReturned to the companyDisposed | −95,000 | –F3 | – | 0 | Direct | |
| Sep 5, 2026 | Common Stock | DReturned to the companyDisposed | −92,200 | –F5 | – | 0 | Direct | |
| Sep 5, 2026 | Common Stock | DReturned to the companyDisposed | −50,000 | –F5 | – | 0 | Direct | |
| Sep 5, 2026 | Common Stock | DReturned to the companyDisposed | −125,000 | –F1 | – | 0 | Direct | |
| Sep 5, 2026 | Common Stock | AGrant or awardAcquired | +65,742 | –F1 | – | 65,742 | Direct | |
| Sep 5, 2026 | Common Stock | AGrant or awardAcquired | +82,608 | –F3 | – | 82,608 | Direct | |
| Sep 5, 2026 | Common Stock | AGrant or awardAcquired | +59,483 | –F5 | – | 59,483 | Direct | |
| Sep 5, 2026 | Common Stock | AGrant or awardAcquired | +32,258 | –F5 | – | 32,258 | Direct | |
| Sep 5, 2026 | Common Stock | AGrant or awardAcquired | +93,984 | –F1 | – | 93,984 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share.
Referenced by the price of 4 transactions in Table II.
- F3
On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.15:1 basis with a post-exchange exercise price of $6.375 per share.
Referenced by the price of 2 transactions in Table II.
- F5
On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share.
Referenced by the price of 4 transactions in Table II.
Remarks
Chief Business Development Officer